Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1984 1
1985 2
1986 3
1987 1
1988 2
1989 1
1990 7
1991 4
1992 5
1993 2
1994 1
1995 4
1996 4
1997 1
1998 5
1999 6
2000 7
2001 4
2002 3
2003 7
2004 6
2005 7
2006 5
2007 9
2008 9
2009 5
2010 6
2011 4
2012 4
2013 7
2014 5
2015 9
2016 10
2017 12
2018 15
2019 14
2020 21
2021 15
2022 9
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Among authors: hochster hs. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Benson AB, et al. Among authors: hochster hs. J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021. J Natl Compr Canc Netw. 2018. PMID: 29632055 Free PMC article.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: hochster h. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. Dasari A, et al. Among authors: hochster h. Nat Rev Clin Oncol. 2020 Dec;17(12):757-770. doi: 10.1038/s41571-020-0392-0. Epub 2020 Jul 6. Nat Rev Clin Oncol. 2020. PMID: 32632268 Free PMC article. Review.
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR. Casulo C, et al. Among authors: hochster hs. Blood. 2022 Mar 17;139(11):1684-1693. doi: 10.1182/blood.2020010263. Blood. 2022. PMID: 34614146 Free PMC article.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Venook AP, et al. Among authors: hochster hs. JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105. JAMA. 2017. PMID: 28632865 Free PMC article. Clinical Trial.
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Kopetz S, et al. Among authors: hochster hs. J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356422 Free PMC article. Clinical Trial.
Introduction.
Ajani JA, Song S, Hochster HS, Steinberg IB. Ajani JA, et al. Among authors: hochster hs. Semin Oncol. 2015 Apr;42 Suppl 1:S1-2. doi: 10.1053/j.seminoncol.2015.02.020. Epub 2015 Feb 19. Semin Oncol. 2015. PMID: 25839663 No abstract available.
Bias and Pancreatic Cancer Reporting.
Hochster HS, Alexander HR. Hochster HS, et al. J Natl Cancer Inst. 2022 May 9;114(5):641-642. doi: 10.1093/jnci/djac020. J Natl Cancer Inst. 2022. PMID: 35157049 Free PMC article. No abstract available.
232 results